僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Cosibelimab （CK-301; TG-1501） is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity （CDC）-mediated killing of PD-L1+ cell lines, including lymphoma cells